UPDATED May 02, 2024
Get exposure to an age-old industry - tobacco.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
LLY * | US$13,339.00 | 6.9% | 74.8% | US$699.4b | US$14,970.14 | PE110.9x | E27.0% | 0.7% | ||
NOVOB N | kr.2,150.39 | 0% | 44.0% | kr.4.0t | kr.2,165.96 | PE47.7x | E14.7% | 1.0% | ||
NVO N | kr.2,227.39 | 2.7% | 55.7% | kr.3.9t | kr.2,311.84 | PE43.4x | E14.6% | 1.1% | ||
JNJ * | US$2,485.00 | -1.7% | -14.3% | US$363.8b | US$2,871.94 | PE21.1x | E7.0% | 3.3% | ||
MRK * | US$2,220.20 | -0.3% | 5.6% | US$326.3b | US$2,451.76 | PE140.9x | E24.9% | 2.4% | ||
ABBV * | US$2,743.00 | -4.8% | 1.5% | US$286.3b | US$3,109.75 | PE47.9x | E23.3% | 3.9% | ||
AZN N | UK£1,300.00 | 0.4% | -2.6% | UK£188.4b | UK£1,408.00 | PE37.3x | E16.5% | 2.0% | ||
TMO * | US$9,760.00 | -0.6% | -0.9% | US$219.5b | US$10,686.39 | PE36.1x | E10.6% | 0.3% | ||
NOVN N | CHF1,719.29 | 0% | n/a | CHF180.4b | CHF1,885.96 | PE26.2x | E10.1% | 3.5% | ||
NVS N | CHF1,540.01 | 0% | -17.7% | CHF181.7b | CHF1,710.24 | PE21.9x | E10.1% | 3.7% | ||
ROG N | CHF4,000.08 | -6.1% | n/a | CHF172.8b | CHF5,066.08 | PE15.3x | E8.6% | 4.4% | ||
AZN1 N | UK£2,196.58 | 0% | -5.5% | UK£147.3b | UK£2,969.10 | PE31.2x | E17.5% | 2.4% | ||
DHR * | US$4,262.83 | 0% | -3.6% | US$182.9b | US$4,709.00 | PE44.9x | E13.5% | 0.4% | ||
PFE * | US$439.99 | 0.9% | -35.8% | US$153.9b | US$506.59 | PE73.5x | E22.0% | 6.1% | ||
AMGN * | US$4,651.04 | 0% | 13.4% | US$148.8b | US$5,060.46 | PE22.2x | E9.1% | 3.2% | ||
SAN1 N | €1,629.20 | 0% | -11.4% | €115.5b | €1,878.23 | PE12.7x | E5.7% | 3.9% | ||
SNY N | €840.00 | 4.7% | -13.6% | €114.8b | €987.72 | PE25.3x | E16.6% | 4.1% | ||
VRTX * | US$6,735.00 | -1.6% | 8.4% | US$103.9b | US$7,746.02 | PE28.6x | E11.4% | n/a | ||
REGN * | US$15,516.00 | 0% | 7.8% | US$97.5b | US$17,168.20 | PE25.6x | E11.4% | n/a | ||
CSL N | AU$3,635.42 | 0% | n/a | AU$145.0b | AU$4,103.81 | PE45.3x | E17.9% | 1.1% | ||
BMY * | US$758.75 | -1.5% | -36.8% | US$89.6b | US$925.74 | PS1.9x | E43.1% | 5.5% | ||
GSK1 N | UK£357.35 | 0% | n/a | UK£69.5b | UK£423.27 | PE15.5x | E11.4% | 3.4% | ||
GSK N | UK£655.00 | 0% | n/a | UK£69.5b | UK£775.84 | PE15.5x | E11.4% | 3.4% | ||
GILD * | US$1,121.00 | -0.07% | -21.7% | US$81.7b | US$1,432.13 | PE168x | E36.7% | 4.7% |